- Adjusted EBITDA Increases 80% to $1.5 Billion in Fourth Quarter 2014 - - $12.8 Billion Full Year Non-GAAP Net Revenue Increases 48% - - $4.5 Billion Full Year Adjusted EBITDA Increases 99% -
- Exceptional Performance across Global Businesses - - GAAP Loss per Diluted Share in Fourth Quarter of $2.76 - - Standalone 2015 Forecast Raised to $16.30-$17.30 - DUBLIN , Feb.
Hotel chain Hilton Worldwide Holdings Inc. (HLT) said on Wednesday that fourth-quarter profit rose to $158 million, or 16 cents a share, up from $26 million, or 3 cents a share, in the year-ago period.
By Barbara Kollmeyer, MarketWatch
Critical information ahead of the U.S. market's open
Limping to the finish line, the S&P 500 closed above 2,100 for the first time ever on Tuesday, delivering year-end target goals to Goldman Sachs, Credit Suisse and Barclays nearly 11 months early.
Allegion plc (NYSE: ALLE), a leading global provider of security
products and solutions, today reported fourth-quarter 2014 net revenues
of $573.5 million and net earnings of $35.6 million, or $0.37 per share
from continuing operations.
Matador Resources Company (NYSE: MTDR) (“Matador” or the “Company”), an
independent energy company engaged in the exploration, development,
production and acquisition of oil and natural gas resources, with an
emphasis on oil and natural gas shale and other unconventional plays and
with a current focus on its Eagle Ford operations in South Texas and its
Permian Basin operations in Southeast New Mexico and West Texas, today
announced plans to release fourth quarter and full year 2014 operational
and financial results after the close of trading on Monday, March 2,
OncoSec Medical Inc. (“OncoSec”) (OTCQB: ONCS ),
a company developing DNA-based intratumoral cancer immunotherapies, and Heat
Biologics, Inc. (“Heat”) (NASDAQ: HTBX) , a clinical stage
biopharmaceutical company focused on the development of cancer
immunotherapies, today announced that they have entered into an
agreement to evaluate the combination of the immunotherapy approaches
developed by each company.
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage
pharmaceutical company focused on the discovery, development and
commercialization of first-in-class therapies for the treatment of
patients with glaucoma and other diseases of the eye, announced today
potentially breakthrough findings from new preclinical research.
Interxion Holding N.V. (NYSE:INXN), a leading European provider of cloud
and carrier-neutral colocation data centre services, announced today
that Giuliano Di Vitantonio has been named Chief Marketing & Strategy
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.